Literature DB >> 10821463

Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children.

B Gröschel1, J J Braner, M Funk, R Linde, H W Doerr, J Cinatl, S Iacobelli.   

Abstract

90K is a secreted serum glycoprotein with immune stimulatory activity. In this study, 90K plasma levels were determined by an enzyme-linked immunosorbent assay in 18 HIV-1-infected children and 10 uninfected control children. 90K levels in HIV-1-infected children (median, 12.5 microg/ml) were higher than in HIV-1 uninfected control group (6.3 microg/ml; P < 0.05). 90K levels of HIV-1-infected children classified as stage B and C (median, 15.0 microg/ml and 22.7 microg/ml, respectively) were higher compared to children with stage A disease (median, 7.0 microg/ml; P < 0.05). A positive correlation (r = 0.5; P < 0.05) was found between 90K levels and HIV-1 RNA levels in 137 plasma samples of 18 HIV-1-infected children collected during a period of 1 year. No correlation was found between 90K levels and CD4 cell counts. These results suggest that 90K plasma levels may represent a novel marker of disease progression in HIV-1-infected children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821463     DOI: 10.1023/a:1006634530672

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

1.  Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals.

Authors:  C Natoli; S Iacobelli; F Ghinelli
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

2.  The predictive value of several markers in the progression to acquired immunodeficiency syndrome.

Authors:  T Planella; M Cortés; C Martínez-Brú; J Barrio; M A Sambeat; F González-Sastre
Journal:  Clin Chem Lab Med       Date:  1998-03       Impact factor: 3.694

Review 3.  British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee.

Authors: 
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

4.  Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.

Authors:  L Perrin; S Yerly; F Marchal; G A Schockmel; B Hirschel; C H Fox; G Pantaleo
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

5.  Tumor-associated antigen 90K activates myelomonocytic cell line THP-1.

Authors:  Z Z Altindag; C Marth; G Werner-Felmayer; C Natoli; A G Zeimet; H Wachter; S Iacobelli; D Fuchs
Journal:  Cancer Lett       Date:  1996-10-01       Impact factor: 8.679

6.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

7.  A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men.

Authors:  N C Briggs; C Natoli; N Tinari; M D'Egidio; J J Goedert; S Iacobelli
Journal:  AIDS Res Hum Retroviruses       Date:  1993-09       Impact factor: 2.205

8.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer.

Authors:  S Iacobelli; E Arnò; A D'Orazio; G Coletti
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

9.  Cloning and expression of a mouse macrophage cDNA coding for a membrane glycoprotein of the scavenger receptor cysteine-rich domain family.

Authors:  Y Chicheportiche; P Vassalli
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

Review 10.  Viral and cellular factors for resistance against antiretroviral agents.

Authors:  B Gröschel; J Cinatl; J Cinatl
Journal:  Intervirology       Date:  1997       Impact factor: 1.763

View more
  9 in total

1.  Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry.

Authors:  Anna Maria Timperio; Federica Gevi; Giuliano Grazzini; Stefania Vaglio; Lello Zolla
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

2.  Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6.

Authors:  Jerome Denard; Cyriaque Beley; Robert Kotin; René Lai-Kuen; Stéphane Blot; Hervé Leh; Aravind Asokan; R Jude Samulski; Philippe Moullier; Thomas Voit; Luis Garcia; Fedor Svinartchouk
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

3.  Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection.

Authors:  Iftach Shaked; David B Hanna; Christian Gleißner; Brenda Marsh; Jill Plants; Daniel Tracy; Kathryn Anastos; Mardge Cohen; Elizabeth T Golub; Roksana Karim; Jason Lazar; Vinayaka Prasad; Phyllis C Tien; Mary A Young; Alan L Landay; Robert C Kaplan; Klaus Ley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03-20       Impact factor: 8.311

4.  Human milk galectin-3 binding protein and breast-feeding-associated HIV transmission.

Authors:  Christina S Chan; Hae-Young Kim; Chloe Autran; Jae H Kim; Moses Sinkala; Chipepo Kankasa; Mwiya Mwiya; Donald M Thea; Grace M Aldrovandi; Louise Kuhn; Lars Bode
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

5.  Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men.

Authors:  David B Hanna; Juan Lin; Wendy S Post; Howard N Hodis; Xiaonan Xue; Kathryn Anastos; Mardge H Cohen; Stephen J Gange; Sabina A Haberlen; Sonya L Heath; Jason M Lazar; Chenglong Liu; Wendy J Mack; Igho Ofotokun; Frank J Palella; Phyllis C Tien; Mallory D Witt; Alan L Landay; Lawrence A Kingsley; Russell P Tracy; Robert C Kaplan
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 7.759

6.  90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1.

Authors:  Veronika Lodermeyer; Kristina Suhr; Nicola Schrott; Christian Kolbe; Christina M Stürzel; Daniela Krnavek; Jan Münch; Christian Dietz; Tanja Waldmann; Frank Kirchhoff; Christine Goffinet
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

Review 7.  A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus.

Authors:  Christoffer T Nielsen; Ole Østergaard; Niclas S Rasmussen; Søren Jacobsen; Niels H H Heegaard
Journal:  Clin Proteomics       Date:  2017-04-08       Impact factor: 3.988

8.  M2BP inhibits HIV-1 virion production in a vimentin filaments-dependent manner.

Authors:  Qin Wang; Xiaolin Zhang; Yuling Han; Xinlu Wang; Guangxia Gao
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

9.  The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K Is Species Specific.

Authors:  Veronika Lodermeyer; George Ssebyatika; Vânia Passos; Aparna Ponnurangam; Angelina Malassa; Ellen Ewald; Christina M Stürzel; Frank Kirchhoff; Margalida Rotger; Christine S Falk; Amalio Telenti; Thomas Krey; Christine Goffinet
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.